Added therapeutic benefit regarding ESMO-MCBS and the French health technology assessment of drugs granted early access program

Ann Oncol. 2022 May;33(5):561-563. doi: 10.1016/j.annonc.2022.02.002. Epub 2022 Feb 14.
No abstract available

Publication types

  • Letter

MeSH terms

  • Financing, Organized
  • Humans
  • Medical Oncology
  • Neoplasms* / drug therapy
  • Technology Assessment, Biomedical*